DE602006012513D1 - Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin - Google Patents

Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Info

Publication number
DE602006012513D1
DE602006012513D1 DE602006012513T DE602006012513T DE602006012513D1 DE 602006012513 D1 DE602006012513 D1 DE 602006012513D1 DE 602006012513 T DE602006012513 T DE 602006012513T DE 602006012513 T DE602006012513 T DE 602006012513T DE 602006012513 D1 DE602006012513 D1 DE 602006012513D1
Authority
DE
Germany
Prior art keywords
treatment
headaches
administering oxytocin
oxytocin
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006012513T
Other languages
English (en)
Inventor
David C Yeomans
Martin S Angst
William H Frey
Daniel I Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HealthPartners Research Foundation
TRIGEMINA Inc
Original Assignee
HealthPartners Research Foundation
TRIGEMINA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HealthPartners Research Foundation, TRIGEMINA Inc filed Critical HealthPartners Research Foundation
Publication of DE602006012513D1 publication Critical patent/DE602006012513D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
DE602006012513T 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin Active DE602006012513D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71195005P 2005-08-26 2005-08-26
US79400406P 2006-04-21 2006-04-21
PCT/US2006/033500 WO2007025249A2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin

Publications (1)

Publication Number Publication Date
DE602006012513D1 true DE602006012513D1 (de) 2010-04-08

Family

ID=37654909

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006012513T Active DE602006012513D1 (de) 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Country Status (9)

Country Link
US (9) US20070093420A1 (de)
EP (3) EP2056800B1 (de)
JP (4) JP5276982B2 (de)
AT (1) ATE458491T1 (de)
AU (1) AU2006282799B2 (de)
CA (2) CA2620202C (de)
DE (1) DE602006012513D1 (de)
IL (1) IL189777A0 (de)
WO (2) WO2007025249A2 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20070093420A1 (en) * 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
IL286053B2 (en) 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
EP3069731A1 (de) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2680704A1 (en) * 2007-03-12 2008-09-18 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
EP2583550A1 (de) * 2007-03-13 2013-04-24 National Jewish Health Verfahren zur Erzeugung von Antikörpern
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US9808509B2 (en) * 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
WO2009012376A1 (en) * 2007-07-17 2009-01-22 The Ohio State University Research Foundation Compositions and methods for skin care
WO2009043479A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100197601A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
EP2205265A1 (de) * 2007-09-11 2010-07-14 Mondobiotech Laboratories AG Verwendung des peptids thymosin beta 4 allein oder in kombination mit cecropin als therapeutisches mittel
RU2010113975A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
WO2009145956A2 (en) * 2008-03-06 2009-12-03 The Trustees Of Columbia University In The City Of New York Uses of calpain inhibitors to inhibit inflammation
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
SG193145A1 (en) * 2008-07-21 2013-09-30 Taiga Biotechnologies Inc Differentiated anucleated cells and method for preparing the same
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
US20110178541A1 (en) * 2008-09-12 2011-07-21 Slender Medical, Ltd. Virtual ultrasonic scissors
WO2010029441A2 (en) * 2008-09-15 2010-03-18 Optinose As Nasal delivery
CA2739936C (en) * 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
WO2010090628A2 (en) * 2008-12-08 2010-08-12 Biousian Biotechnology, Inc Delta-opioid receptor selective analgesics
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
JP5669145B2 (ja) * 2009-07-02 2015-02-12 国立大学法人山口大学 表面麻酔剤
SG177752A1 (en) * 2009-07-27 2012-03-29 Trigemina Inc Methods for treatment of pain
FR2948809B1 (fr) * 2009-07-31 2012-08-17 St Microelectronics Rousset Amplificateur de lecture faible puissance auto-minute
US8623366B2 (en) 2009-08-28 2014-01-07 Labrys Biologics, Inc. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN102695545B (zh) 2009-09-08 2016-08-17 特色疗法股份有限公司 包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物
AU2010330747B2 (en) * 2009-12-18 2016-08-11 Achelios Therapeutics, Inc. Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
US20110184322A1 (en) * 2010-01-22 2011-07-28 Slender Medical Ltd. Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
CN102892289B (zh) 2010-03-03 2015-03-25 尼昂克技术公司 包含单萜的药物组合物
EP2560486B1 (de) 2010-04-21 2018-11-21 Signature Therapeutics, Inc. Zusammensetzungen aus enzymspaltbaren amphetamin-prodrugs und hemmern dafür
WO2011133179A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable hydromorphone prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US8617150B2 (en) 2010-05-14 2013-12-31 Liat Tsoref Reflectance-facilitated ultrasound treatment
US8956346B2 (en) 2010-05-14 2015-02-17 Rainbow Medical, Ltd. Reflectance-facilitated ultrasound treatment and monitoring
US9242122B2 (en) 2010-05-14 2016-01-26 Liat Tsoref Reflectance-facilitated ultrasound treatment and monitoring
CA2799733A1 (en) 2010-05-18 2011-11-24 Universite De Geneve New uses of oxytocin-like molecules and related methods
BR112013000190A2 (pt) * 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2883543B1 (de) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmazeutische Zusammensetzungen mit Perillylalcohol-Carbamaten
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
US8647661B1 (en) * 2010-11-05 2014-02-11 Florida A&M University Surface modified multilayered nanostructures for dermal delivery
BR112013015107B1 (pt) 2010-12-17 2022-03-22 Neonc Technologies Inc. Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
EP2663187B1 (de) 2011-01-11 2016-06-01 Signature Therapeutics, Inc. Zusammensetzungen mit einem enzymspaltbaren oxycodon-prodrug
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10687975B2 (en) * 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
PT2694049T (pt) 2011-04-05 2019-02-06 Gruenenthal Gmbh Tapentadol para prevenir a cronicidade da dor
US20120309840A1 (en) * 2011-04-05 2012-12-06 Gruenenthal Gmbh Treatment of Pain Associated with Trigeminal Neuralgia
SI2701693T1 (sl) 2011-04-29 2017-11-30 Gruenenthal Gmbh Tapentadol za preprečevanje in zdravljenje depresije in anksioznosti
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) * 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
AU2013207346A1 (en) * 2012-01-05 2014-06-05 Beech Tree Labs, Inc. Method of treating pain by administration of Nerve Growth Factor
US9707414B2 (en) 2012-02-14 2017-07-18 Rainbow Medical Ltd. Reflectance-facilitated ultrasound treatment and monitoring
CA2864606C (en) 2012-02-15 2021-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
EP2914192B1 (de) 2012-11-05 2019-05-01 Pythagoras Medical Ltd. Gesteuerte gewebeablation
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
AU2013352223B2 (en) * 2012-11-28 2019-07-18 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
US9050330B2 (en) * 2012-12-06 2015-06-09 Jose C. Ramon-de-Jesus Method, composition and kit for treating frequent headaches
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
MX2015013181A (es) 2013-03-15 2015-12-11 Amgen Inc Anticuerpos humanos pac1.
KR20220119187A (ko) 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
CN106456759A (zh) 2014-03-21 2017-02-22 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10478249B2 (en) 2014-05-07 2019-11-19 Pythagoras Medical Ltd. Controlled tissue ablation techniques
CA2952622A1 (en) * 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
JP6607509B2 (ja) * 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
PL3200764T3 (pl) 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
US9532944B2 (en) 2014-10-20 2017-01-03 Oyster Point Pharma, Inc. Methods of improving ocular discomfort
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
CA2962466C (en) 2014-10-21 2023-01-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
AU2015348297A1 (en) 2014-11-19 2017-05-25 Optinose As Intranasal administration
EP3226972A4 (de) * 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von migräne und leiden in zusammenhang mit schmerzen
CN107847552B (zh) * 2015-01-07 2022-07-01 三叉神经股份公司 含镁的催产素制剂和使用方法
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
JP6734258B2 (ja) * 2015-03-04 2020-08-05 栄研化学株式会社 オキシトシンの高感度測定法
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
JP7093559B2 (ja) * 2016-04-12 2022-06-30 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2018094376A1 (en) * 2016-11-21 2018-05-24 uBiome, Inc. Method and system for characterizing a headache-related condition
EP3547836A4 (de) 2016-11-30 2020-08-05 Neonc Technologies Inc. Perillylalkohol-3 bromopyruvat-konjugat und verfahren zur behandlung von krebs
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
EP3737699A1 (de) * 2018-01-12 2020-11-18 Amgen Inc. Pac1-antikörper und verwendungen davon
WO2019157195A1 (en) 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
WO2021016190A1 (en) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for modulating drug-use disorders
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
JP2022546703A (ja) * 2019-08-29 2022-11-07 ニューヨーク ユニバーシティ 耳鳴りの治療のためのオキシトシン組成物
US20240100120A1 (en) * 2019-10-11 2024-03-28 Board Of Regents, The University Of Taxas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
JP2024518860A (ja) * 2020-08-10 2024-05-08 ジロパ・インコーポレイテッド 局所送達用組成物及び方法
WO2023146579A1 (en) * 2022-01-27 2023-08-03 Belnap Pharmaceuticals, Llc Methods of treatment using oxytocin

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413A (en) * 1849-05-01 Improved method of making wire-strengthened spoons
US464378A (en) * 1891-12-01 Toilet-paper holder
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) * 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
ATE99543T1 (de) * 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
AU6909091A (en) * 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
DE4312913A1 (de) * 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
WO1996020001A1 (fr) * 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Preparation traversant la muqueuse
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997031626A1 (fr) * 1996-02-27 1997-09-04 Teijin Limited Composition pulverulente destinee a une adminstration nasale
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
DE69928563T2 (de) * 1998-12-09 2006-07-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
EP1135105B1 (de) 1998-12-09 2005-03-02 Chiron Corporation Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
TR200103613T2 (tr) * 1999-06-16 2004-08-23 Nastech Pharmaceutical Co., Inc. Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) * 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
JP2004512260A (ja) * 2000-04-28 2004-04-22 メモリアル　スローン−ケッタリング　キャンサー　センター 局所麻酔／オピオイド製剤およびその使用方法
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20020082215A1 (en) * 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
EP1370275B1 (de) 2001-03-23 2010-05-26 Albert Einstein College Of Medicine Of Yeshiva University Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US20030165434A1 (en) * 2001-04-20 2003-09-04 Chiron Corporation Delivery of polynucleotide agents to the central nervous system
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
EP1501532A4 (de) * 2002-04-22 2007-11-14 Univ Leland Stanford Junior Peptid-hemmer der protein-kinase c
AU2003229735A1 (en) 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
EP1551457A1 (de) * 2002-07-16 2005-07-13 Elan Pharma International Limited Flüssige dosierzusammensetzungen von stabilen wirkstoffen in nanoteilchenform
AU2003273247A1 (en) 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
US7065445B2 (en) * 2002-11-27 2006-06-20 Mobilearia Vehicle passive alert system and method
WO2004062563A2 (en) 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
ES2315455T3 (es) * 2003-03-27 2009-04-01 Pantarhei Bioscience B.V. Uso de estrogenos para el tratamiento de infertilidad en maniferos machos.
EP1615655B1 (de) 2003-04-08 2012-02-22 Biotempt B.V. Verwendung von hcg-fragmente enthaltene zusammensetzungen zur mukosalen und oralen anwendung
US20040229025A1 (en) * 2003-04-11 2004-11-18 Chen Zhang Voltage tunable photodefinable dielectric and method of manufacture therefore
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
EP1742626A2 (de) 2004-04-23 2007-01-17 The Regents of The University of California Verbindungen und verfahren zur behandlung nichtentzündlicher schmerzen mit pparalpha-agonisten
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
KR20070110087A (ko) * 2005-02-23 2007-11-15 알자 코포레이션 중추신경계에 활성 약제의 비강 투여
EP2455072A1 (de) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Octreotid-Formulierungen mit kontrollierter Freisetzung
US20060252685A1 (en) * 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
US20070093420A1 (en) * 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
CN101404174B (zh) * 2007-10-04 2010-06-09 威刚科技股份有限公司 电子信息储存装置

Also Published As

Publication number Publication date
WO2007025249A2 (en) 2007-03-01
EP2179741A1 (de) 2010-04-28
WO2007025249A3 (en) 2007-04-19
EP1928484B1 (de) 2010-02-24
JP2013060464A (ja) 2013-04-04
JP5276982B2 (ja) 2013-08-28
EP2056800A2 (de) 2009-05-13
US20100080797A1 (en) 2010-04-01
US8258096B2 (en) 2012-09-04
US20090291900A1 (en) 2009-11-26
US8198240B2 (en) 2012-06-12
JP2009506076A (ja) 2009-02-12
US20070093420A1 (en) 2007-04-26
IL189777A0 (en) 2008-08-07
US20120028898A1 (en) 2012-02-02
CA2620364A1 (en) 2007-03-01
EP1928484A2 (de) 2008-06-11
US20120322736A1 (en) 2012-12-20
US20070054843A1 (en) 2007-03-08
ATE458491T1 (de) 2010-03-15
US20090317377A1 (en) 2009-12-24
WO2007025286A3 (en) 2007-05-10
US8252745B2 (en) 2012-08-28
CA2620202A1 (en) 2007-03-01
JP5670415B2 (ja) 2015-02-18
AU2006282799B2 (en) 2012-11-29
AU2006282799A1 (en) 2007-03-01
US8501691B2 (en) 2013-08-06
CA2620202C (en) 2016-10-04
US8202838B2 (en) 2012-06-19
EP2179741B1 (de) 2014-10-15
EP2056800B1 (de) 2015-12-09
US20110250212A1 (en) 2011-10-13
JP2012207046A (ja) 2012-10-25
JP2009506071A (ja) 2009-02-12
US20090181880A1 (en) 2009-07-16
WO2007025286A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DE602006012513D1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
ATE497492T1 (de) Reinigung von montelukast
EA201070247A1 (ru) Ингибиторы протеасом
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
EA200802054A1 (ru) Ингибиторы фермента
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005020743D1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
DE602006013115D1 (de) Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
EA202091708A1 (ru) Ингибиторы днк-пк
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition